A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in
treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a
VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking
blood flow to the tumor.